MedPath

Minocycline to Treat Amyotrophic Lateral Sclerosis

Phase 3
Completed
Conditions
Amyotrophic Lateral Sclerosis
Registration Number
NCT00047723
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Brief Summary

The purpose of this trial is to test the safety, tolerability, and effectiveness of minocycline compared to placebo in patients with amyotrophic lateral sclerosis (ALS).

Detailed Description

ALS is a progressive neurodegenerative disorder without cure or known treatment that significantly improves function. Loss of motor neurons in the brain and spinal cord of ALS patients causes the progressive symptoms. Laboratory studies have linked inducible nitric oxide synthase (iNOS) and caspase enzyme activation to motor nerve cell death in ALS. Minocycline-a medication currently approved by the FDA for treatment of bacterial infections-is a tetracycline antibiotic with high central nervous system penetration when taken orally. The drug inhibits the activity of iNOS and caspase enzymes.

Minocycline has been tested and shown to protect nerve cells in many scientific experiments. It reduces cell death and prolongs survival in animal models of ALS, stroke, trauma, Huntington's disease, and Parkinson's disease. It has been shown to be beneficial in many different animal experiments of ALS, conducted in Europe, Canada and the United States.

Minocycline has been tested in 2 preliminary human trials and has been shown to be safe in patients with ALS. It has been well tolerated in conjunction with riluzole (Rilutek), the only currently FDA-approved medication for ALS.

This trial is the final important step in determining whether minocycline improves the course of ALS. The principle objective of this clinical trial is to determine whether minocycline slows disease progression and helps maintain function in patients with ALS. This multi-center placebo-controlled study will select patients early in the course of ALS, when a neuroprotective therapy may be most beneficial. The study will measure change in function (as detected by ALSFRS-R scores), strength, pulmonary function, survival, and quality of life. Participants will undergo monthly outpatient evaluations and analysis of laboratory and adverse events. This is a 13-month study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
400
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in function as detected by the ALS Functional Rating Scale (ALSFRS-R) in patients taking minocycline compared to those taking placebo.
Secondary Outcome Measures
NameTimeMethod
Changes in manual muscle testing (MMT), forced vital capacity (FVC, percent predicted), quality of life (QOL) and survival

Trial Locations

Locations (29)

Drexel University College of Medicine, Hahnemann Campus

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

University of Vermont

๐Ÿ‡บ๐Ÿ‡ธ

Burlington, Vermont, United States

Methodist Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Houston, Texas, United States

Virginia Mason Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Seattle, Washington, United States

University of Kentucky

๐Ÿ‡บ๐Ÿ‡ธ

Lexington, Kentucky, United States

University of California, Irvine

๐Ÿ‡บ๐Ÿ‡ธ

Irvine, California, United States

University of New Mexico

๐Ÿ‡บ๐Ÿ‡ธ

Albuquerque, New Mexico, United States

University of Illinois

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Indiana University School of Medicine

๐Ÿ‡บ๐Ÿ‡ธ

Indianapolis, Indiana, United States

Wake Forest University

๐Ÿ‡บ๐Ÿ‡ธ

Winston- Salem, North Carolina, United States

University of California Department of Neurology

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Mayo Clinic

๐Ÿ‡บ๐Ÿ‡ธ

Jacksonville, Florida, United States

University of Iowa

๐Ÿ‡บ๐Ÿ‡ธ

Iowa City, Iowa, United States

Columbia Unversity, Eleanor and Lou Gehrig MDA/ALS Center

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Metro Health Clinic

๐Ÿ‡บ๐Ÿ‡ธ

Cleveland, Ohio, United States

UMDNJ/Robert Wood Johnson Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

New Brunswick, New Jersey, United States

University of Texas Southwestern

๐Ÿ‡บ๐Ÿ‡ธ

Dallas, Texas, United States

University of Pennsylvania

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Carolinas Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Charlotte, North Carolina, United States

Washington University

๐Ÿ‡บ๐Ÿ‡ธ

St. Louis, Missouri, United States

California Pacific Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

San Francisco, California, United States

Univ. of Colorado Health Sciences Center

๐Ÿ‡บ๐Ÿ‡ธ

Denver, Colorado, United States

Hennepin County Med Center

๐Ÿ‡บ๐Ÿ‡ธ

Minneapolis, Minnesota, United States

University of Minnesota

๐Ÿ‡บ๐Ÿ‡ธ

Minneapolis, Minnesota, United States

Duke University

๐Ÿ‡บ๐Ÿ‡ธ

Durham, North Carolina, United States

Oregon Health & Science University

๐Ÿ‡บ๐Ÿ‡ธ

Portland, Oregon, United States

University of Texas Health Sciences Center

๐Ÿ‡บ๐Ÿ‡ธ

San Antonio, Texas, United States

University of Utah

๐Ÿ‡บ๐Ÿ‡ธ

Salt Lake City, Utah, United States

University of Kansas Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Kansas City, Kansas, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath